Nasal septal perforation from bevacizumab: A discussion of outcomes, management, and pharmacovigilance

Judi Anne B. Ramiscal, Aminah Jatoi

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

To date, the published literature describes 18 reports of nasal septal perforation in cancer patients with the administration of bevacizumab. This complication was detected during post-marketing surveillance of bevacizumab. How should patients who develop this complication be managed? This discussion summarizes suggestions for management of bevacizumab-associated nasal septal perforation and, as relevant to healthcare providers, discusses some of the practical aspects of post-marketing pharmacovigilance.

Original languageEnglish (US)
Pages (from-to)307-310
Number of pages4
JournalCurrent oncology reports
Volume14
Issue number4
DOIs
StatePublished - Aug 1 2012

Keywords

  • Bevacizumab
  • Epistaxis
  • Nasal septal perforation
  • Pharmacovigilance

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Nasal septal perforation from bevacizumab: A discussion of outcomes, management, and pharmacovigilance'. Together they form a unique fingerprint.

  • Cite this